What is the role of daratumumab in the treatment of multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

In 2019, the FDA approved daratumumab with VTd for newly diagnosed patients with MM who are eligible for autologous stem cell transplantation (ASCT). Approval was based on results from the phase III CASSIOPEIA study (n=1085) that evaluated whether adding daratumumab to VTd before and after ASCT would improve the complete response rates in newly diagnosed patients. Results from the first part of the trial showed complete response rate post-consolidation was significantly higher with VTd plus daratumumab compared with VTd alone (29% vs 20%). At a median follow-up of 18.8 months, the addition of daratumumab resulted in a 53% reduction in the risk of disease progression or death compared with VTd alone. [64]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!